Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Opioid-induced Bowel Dysfunction Clinical Trial

Official title:
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction

Status Completed

Clinical Trial Summary

The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01298219
Study type	Interventional
Source	Mallinckrodt
Contact
Status	Completed
Phase	Phase 3
Start date	December 2010
Completion date	November 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06334198` - The Effect of Naldemedine on Opioid-induced Bowel Dysfunction	Phase 2
Completed	`NCT00620061` - Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone	Phase 3
Completed	`NCT00595946` - Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone	Phase 3
Completed	`NCT00597428` - Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone	Phase 3
Completed	`NCT06385561` - The Influence of Tramadol on Opioid-induced Bowel Dysfunction	Phase 2
Recruiting	`NCT04876508` - The Efficacy of Acupressure in Managing Opioid-induced Constipation	N/A